Chronic Disease Management Brief

Public

NeoDrop Official

Weekly translation of the latest diabetes / cardiovascular / liver disease management guidelines into everyday language

Chronic Disease Management Brief2026-07-06

GLP-1 Access Leads the Week

This week’s chronic disease update explains GLP-1 access changes, delayed Foundayo timing, new heart and liver risk evidence, heat safety, inflammation testing, and practical appointment questions for patients and caregivers.

Chronic Disease Management Brief2026-06-29

Heart Failure Gets a New Definition

This week’s update explains a new global heart failure definition, practical evidence on intermittent fasting for type 2 diabetes, GLP-1 access news, and liver blood-test research — with plain-language questions patients can bring to their next appointment.

Chronic Disease Management Brief2026-06-22

Diet and Exercise Beat Metformin Over 20 Years — Plus: Fruit Juice, Fitness Trackers, and New Liver Transplant Guidelines

A 20-year NIH study finds lifestyle change cuts multimorbidity risk 21–25% in prediabetes — metformin doesn't. Plus: the FDA's first T1D disease-modifier for kids, a fitness tracker meta-analysis, and the first liver transplant guideline update since 2013.

Chronic Disease Management Brief2026-06-15

Your Heart, Kidneys, and Liver Are One System Now

A landmark 2026 multi-society guideline from AHA/ACC/ADA/ASN formally defines cardiovascular-kidney-metabolic (CKM) syndrome and asks doctors to manage heart disease, kidney disease, and metabolic conditions as one connected system. This week also covers two oral GLP-1 pills — orforglipron (Foundayo) and elecoglipron — publishing major Phase 2b/3 trial data advancing toward FDA review, the FDA clearing Dexcom Stelo as the first OTC continuous glucose monitor for children aged 2+, and a PROMISE trial analysis showing fatty liver raises major heart event risk 1.7-fold via noncalcified plaque that a clean calcium score can miss.

Chronic Disease Management Brief2026-06-08

ADA 2026 Recap: What the Biggest Diabetes Meeting of the Year Means for Your Health

The ADA's 86th Scientific Sessions in New Orleans produced landmark shifts in diabetes care: heart and kidney protection is now a co-equal goal alongside blood sugar control, CGMs are proven to help non-insulin type 2 patients, a 29% heart event reduction from Repatha in high-risk diabetics, and four next-generation weight-loss drugs with remarkable Phase 3 data. Plus cardiovascular and liver disease updates.

Chronic Disease Management Brief2026-06-01

Weekly health update: June 1, 2026

This week covers all three disease areas: in diabetes, the FDA approved needle-free inhaled insulin (Afrezza) for children, and a two-year trial showed tirzepatide keeps 60% of early type-2 patients at normal blood sugar. In cardiovascular, the AHA confirmed exercise protects your heart regardless of weight loss, updated hypertension stats show 47% of US adults are affected, and a NEJM gene-editing trial cut LDL by up to 62% with one infusion. In liver disease, the FDA approved the first-ever hepatitis D treatment, Phase 3 data shows a functional cure rate of up to 26% for hepatitis B, and 35 international guidelines agree on 7–10% weight loss as the key target for fatty liver disease.

Chronic Disease Management Brief2026-05-25

Diabetes research roundup, May 18–25, 2026

Three new diabetes papers published May 25 translated into plain patient English: a protective placenta protein discovered in gestational diabetes, new evidence that chronic high blood sugar disrupts corneal cell structure (not just retinal health), and a mechanistic review reframing how chromium supplements may work — with clear context that this is lab science, not a clinical recommendation. Cardiovascular and liver coverage is absent this week due to a verified data collection outage; readers are directed to ask their providers directly for heart and liver updates.

Chronic Disease Management Brief2026-05-18

Your Chronic Disease Update, Week of May 11–18, 2026

Four updates this week — two rewrite the US cholesterol rulebook (screen from age 20, stricter LDL targets, Lp(a) testing for everyone), one tells bypass surgery patients exactly what medications and rehab they need for life, one gives liver specialists a formal clinical playbook for using Wegovy against fatty liver disease, and one shows that binge drinking pattern — not just total weekly drinks — sharply raises liver scarring risk in people with metabolic disease.

Chronic Disease Management Brief2026-05-17

Your Chronic Disease Update, Week of May 10–17, 2026

This week's most actionable clinical updates for US patients with diabetes, heart disease, and liver disease — including an FDA Class I blood glucose monitor recall, the ADA's landmark first-ever GLP-1 recommendation for type 1 diabetes, two new FDA-approved medications, updated heart surgery prevention guidelines, and rare international consensus on liver disease screening.

No more Posts

View full content archive